111 related articles for article (PubMed ID: 16365596)
1. IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity.
Nair RE; Jong YS; Jones SA; Sharma A; Mathiowitz E; Egilmez NK
J Immunother; 2006; 29(1):10-20. PubMed ID: 16365596
[TBL] [Abstract][Full Text] [Related]
2. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
Nair RE; Kilinc MO; Jones SA; Egilmez NK
J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
[TBL] [Abstract][Full Text] [Related]
4. Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation.
Rowswell-Turner RB; Harden JL; Nair RE; Gu T; Kilinc MO; Egilmez NK
J Immunol; 2011 Oct; 187(8):4109-18. PubMed ID: 21908736
[TBL] [Abstract][Full Text] [Related]
5. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.
Wolpoe ME; Lutz ER; Ercolini AM; Murata S; Ivie SE; Garrett ES; Emens LA; Jaffee EM; Reilly RT
J Immunol; 2003 Aug; 171(4):2161-9. PubMed ID: 12902523
[TBL] [Abstract][Full Text] [Related]
7. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
[TBL] [Abstract][Full Text] [Related]
8. CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells.
Lindencrona JA; Preiss S; Kammertoens T; Schüler T; Piechocki M; Wei WZ; Seliger B; Blankenstein T; Kiessling R
Int J Cancer; 2004 Mar; 109(2):259-64. PubMed ID: 14750178
[TBL] [Abstract][Full Text] [Related]
9. Transient activation of tumor-associated T-effector/memory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease.
Gu T; Kilinc MO; Egilmez NK
Cancer Immunol Immunother; 2008 Jul; 57(7):997-1005. PubMed ID: 18049819
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant intratumoral cytokine-loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti-tumor immunity.
Arora A; Su G; Mathiowitz E; Reineke J; Chang AE; Sabel MS
J Surg Oncol; 2006 Oct; 94(5):403-12. PubMed ID: 16967445
[TBL] [Abstract][Full Text] [Related]
11. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
[TBL] [Abstract][Full Text] [Related]
12. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
[TBL] [Abstract][Full Text] [Related]
13. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.
Murata S; Ladle BH; Kim PS; Lutz ER; Wolpoe ME; Ivie SE; Smith HM; Armstrong TD; Emens LA; Jaffee EM; Reilly RT
J Immunol; 2006 Jan; 176(2):974-83. PubMed ID: 16393983
[TBL] [Abstract][Full Text] [Related]
14. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity.
Sabel MS; Skitzki J; Stoolman L; Egilmez NK; Mathiowitz E; Bailey N; Chang WJ; Chang AE
Ann Surg Oncol; 2004 Feb; 11(2):147-56. PubMed ID: 14761917
[TBL] [Abstract][Full Text] [Related]
16. Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor.
Zilocchi C; Stoppacciaro A; Chiodoni C; Parenza M; Terrazzini N; Colombo MP
J Exp Med; 1998 Jul; 188(1):133-43. PubMed ID: 9653090
[TBL] [Abstract][Full Text] [Related]
17. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
[TBL] [Abstract][Full Text] [Related]
18. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
Takeuchi N; Hiraoka S; Zhou XY; Nagafuku M; Ono S; Tsujimura T; Nakazawa M; Yura Y; Hamaoka T; Fujiwara H
Cancer Res; 2004 Oct; 64(20):7588-95. PubMed ID: 15492286
[TBL] [Abstract][Full Text] [Related]
19. Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu.
Bergman I; Griffin JA; Gao Y; Whitaker-Dowling P
Int J Cancer; 2007 Jul; 121(2):425-30. PubMed ID: 17354238
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells.
Morales JK; Kmieciak M; Graham L; Feldmesser M; Bear HD; Manjili MH
Cancer Immunol Immunother; 2009 Jun; 58(6):941-53. PubMed ID: 18979098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
